Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What do the statin trials tell us?

D D Waters

    The American Journal of Managed Care
    |June 1, 2001
    PubMed
    Summary

    Statins significantly lower the risk of coronary events, with benefits increasing over time and with greater reduction in low-density lipoprotein cholesterol (LDL-C). These cholesterol-lowering drugs are safe and effective across diverse patient groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Action of nifedipine in ischemic heart disease.

    Canadian family physician Medecin de famille canadien·2011
    Same author

    Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.

    Neurology·2010
    Same author

    Do statins confer early benefit after acute coronary syndromes? The results from FLORIDA.

    European heart journal·2002
    Same author

    Short- and medium-term outcome differences in women and men after primary percutaneous transluminal mechanical revascularization for acute myocardial infarction.

    The American journal of cardiology·2002
    Same author

    Comparison of electrocardiographic-gated technetium-99m sestamibi single-photon emission computed tomographic imaging and rest-redistribution thallium-201 in the prediction of myocardial viability.

    The American journal of cardiology·2002
    Same author

    Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines.

    Circulation·2001

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Background:

    • Coronary artery disease (CAD) poses a significant health risk.
    • Statins are a class of lipid-lowering medications.
    • Understanding the long-term efficacy and safety of statins is crucial.

    Purpose of the Study:

    • To evaluate the effects of statins on coronary events.
    • To assess the relationship between statin therapy duration, LDL-C reduction, and event rates.
    • To determine the safety and effectiveness of statins in specific populations.

    Main Methods:

    • Analysis of 5 major placebo-controlled trials.
    • Inclusion of approximately 31,000 individuals with and without known coronary disease.
    • Evaluation of outcomes including coronary events, stroke, and transient ischemic attacks.

    Main Results:

    • Statins reduce the incidence of coronary events.
    • Risk reduction is proportional to low-density lipoprotein cholesterol (LDL-C) reduction and therapy duration.
    • Statins are safe and effective in women, diabetics, and older adults (>65 years).
    • Reduced risk of stroke and transient ischemic attacks observed in patients with coronary disease.

    Conclusions:

    • Statins offer significant cardiovascular benefits by reducing coronary events.
    • Lowering LDL-C levels through statin therapy is directly linked to decreased event rates.
    • Statins positively impact pathophysiologic processes contributing to atherosclerosis and are well-tolerated across various demographics.

    Related Experiment Videos